{
  "id": "51595fb0d24251bc0500009c",
  "type": "list",
  "question": "Proteomic analyses have revealed proteins associated with the triple-negative breast cancers. List some proposed proteins.",
  "ideal_answer": "Selected proteins of interest proposed from triple-negative cancer proteomic studies are CD44, PARP1, Mage-A4, LSR, RAB25, S100A14, MUC1, Hsp90, Actin, 14-3-3, vimentin, HSP70, CK18, moesin, IDH2, CRABP2, SEC14L2, beta-catenin, MUC18, Stat1 and CD74.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/19416831",
    "http://www.ncbi.nlm.nih.gov/pubmed/23172894",
    "http://www.ncbi.nlm.nih.gov/pubmed/22414580",
    "http://www.ncbi.nlm.nih.gov/pubmed/20068102",
    "http://www.ncbi.nlm.nih.gov/pubmed/22692575",
    "http://www.ncbi.nlm.nih.gov/pubmed/19485423",
    "http://www.ncbi.nlm.nih.gov/pubmed/23436753",
    "http://www.ncbi.nlm.nih.gov/pubmed/22178447",
    "http://www.ncbi.nlm.nih.gov/pubmed/22934887",
    "http://www.ncbi.nlm.nih.gov/pubmed/21630460",
    "http://www.ncbi.nlm.nih.gov/pubmed/20005186"
  ],
  "snippets": [
    {
      "text": "Some of these proteins are of outstanding interest in the biology and clinical management of this disease, such as CD44 and PARP1.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23436753",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "We present here our results, including a large cumulative database of proteins based on the analysis of 78 TNBCs, and the identification and validation of one specific protein, Mage-A4, which was expressed in a significant fraction of TNBC and Her2-positive/ER negative lesions.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23172894",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23172894",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Further, we performed comparative quantitative proteomic and gene array analyses of these cells and identified potential novel markers of breast cancer cells with tumor-initiating features, such as lipolysis-stimulated lipoprotein receptor (LSR), RAB25, S100A14 and mucin 1 (MUC1), as well as a novel 31-gene signature capable of predicting distant metastasis in cohorts of estrogen receptor-negative human breast cancers.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22692575",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "he results identify Hsp90 as a critical and multimodal target in this most difficult to treat breast cancer subtype and support the use of the Hsp90 inhibitor PU-H71 for clinical trials involving patients with TNBC.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19416831",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "We obtained differential expression patterns for several glycolytic enzymes (as for example MDH2, PGK1, TKT, Aldolase1), cytokeratins (CK7, 8, 9, 14, 17, 19), further structure proteins (vimentin, fibronectin, L-plastin), for NME1-NME2, lactoferrin, and members of the Annexin family.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19485423",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "he expression of calreticulin, cellular retinoic acid-binding protein II, chloride intracellular channel protein 1, EF-1-beta, galectin 1, peroxiredoxin-2, platelet-derived endothelial cell growth factor, protein disulfide isomerase and ubiquitin carboxyl-terminal hydrolase 5 were further validated using a tissue microarray containing 70 malignant breast carcinomas of various grades of atypia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20005186",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "The first is characterized by high expression of Stat1, Mx1, and CD74.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22178447",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "This effect was accompanied with a marked increase in the membrane expression of beta-catenin, MUC18, plexins, integrins, and other proteins involved in cell adhesion and cancer metastasis. Taken together, our results show that Stat1/CD74 positive triple-negative tumors are more aggressive and suggest an approach for development of better diagnostics and more targeted therapies for triple negative breast cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22178447",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Proteomic analysis also identified high levels of IDH2 and CRABP2 and low levels of SEC14L2 to be prognostic markers for overall breast cancer survival.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22414580",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Proteomic and validation immunohistochemical analyses revealed that alpha-defensins (DEFA) were overexpressed in tumors from patients with a pCR.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20068102",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "The expression of a selected group of high abundance and/or breast cancer-specific potential biomarkers including thromobospondin 1, galectin-3 binding protein, cathepsin D, vimentin, zinc-\u03b12-glycoprotein, CD44, and EGFR from the breast cancer cell lines and in their culture media were further validated by Western blot analysis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22934887",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "his provided novel evidence for PMA regulation of the enzymes glyceraldehyde-3-phosphate dehydrogenase, nucleolar RNA helicase 2 and Heterogeneous nuclear ribonucleoprotein M.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21630460",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Among them, we identify downregulation of components of the Ras/Raf/MAPK pathway and G(2)-M phase to contribute to its anti-proliferative effect, degradation of activated Akt and Bcl-xL to induce apoptosis, and inhibition of activated NF-kappaB, Akt, ERK2, Tyk2, and PKC to reduce TNBC invasive potential.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19416831",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    }
  ],
  "concepts": [
    "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020543",
    "http://www.disease-ontology.org/api/metadata/DOID:0060081",
    "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D040901"
  ],
  "exact_answer": "CD44, PARP1, Mage-A4, LSR, RAB25, S100A14, MUC1, Hsp90, Actin, 14-3-3, vimentin, HSP70, CK18, moesin, IDH2, CRABP2, SEC14L2, beta-catenin, MUC18, Stat1, CD74"
}